Application No. 10/738.317 Docket No.: 65306-0092 Amendment dated July 16, 2008

Non-Final Office Action of January 17, 2008

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for forming an endovascular occlusion comprising the step

of controlling injection of a purified alginate liquid and injection of a calcium chloride solution to a

targeted area within a vascular system, wherein the injection of the purified alginate liquid and

injection of the calcium chloride solution are at variable injection rates, either within an injection stage or across injection stages, and wherein the purified liquid alginate is of a molecular weight

from about 65,000 g/mol to about 200,000 g/mol.

2.-4. (Canceled).

5. (Canceled)

6. The method according to claim 1, wherein the injection flow rate of the (Original)

calcium chloride solution is variable during injection.

The method according to claim 1, wherein injection of the calcium chloride 7. (Original)

solution occurs at staged intervals.

8. (Canceled)

9. (Canceled)

10. (Original) The method according to claim 1, wherein the injection flow rate of the

alginate liquid solution is variable during injection.

The method according to claim 1, wherein injection of the alginate liquid 11. (Original)

solution occurs at staged intervals.

The method according to claim 1, wherein the injection flow rates of the 12. (Original)

alginate liquid and the calcium chloride solution are about equal during injection.

2

Application No. 10/738.317 Docket No : 65306-0092

Amendment dated July 16, 2008 Non-Final Office Action of January 17, 2008

The method according to claim 1, wherein the injection flow rates of the 13. (Original)

alginate liquid and the calcium chloride solution are different during injection.

14. (Original) The method according to claim 1, wherein injection of the alginate liquid and

injection of the calcium chloride solution occur at staged intervals.

15. (Original) The method according to claim 1, wherein one or more agents are added to

the alginate liquid during the controlled injection.

The method according to claim 15, wherein the one or more agents are

16. (Original)

selected from the group consisting of therapeutic drugs, radioactive or contrast agents, growth

enhancers or inhibitors, or any combination thereof.

(Currently Amended) A method for forming an endovascular occlusion comprising the steps 17.

of:

Providing a catheter comprised of at least two lumens, and a.

b. Forming a calcium alginate polymer in a targeted area within a vascular system by

controlling injection of a purified alginate liquid and injection of a calcium chloride solution to the

targeted area through the catheter, wherein the polymer is formed external to the catheter within the

target site and wherein injection of the purified alginate liquid and injection of the calcium chloride

solution are at variable injection rates, either within an injection stage or across injection stages, and wherein the purified alginate liquid is of molecular weight from about 65.000 g/mol to about

200,000 g/mol.

18-20. (Canceled).

The method according to claim 17, wherein the at least two lumens are 21 (Original)

concentric.

22. (Canceled).

3

Application No. 10/738,317 Docket No.: 65306-0092

Amendment dated July 16, 2008 Non-Final Office Action of January 17, 2008

23. (Currently Amended) A method for forming an endovascular occlusion comprising the steps of

- a. providing at least one assist device to a targeted area in a vascular system, and
- b. controlling injection of a purified alginate liquid and injection of a calcium chloride solution to the targeted area, wherein injection of the alginate liquid and injection of the calcium chloride solution are at variable injection rates, either within an injection stage or across injection stages, and wherein the purified alginate liquid is of molecular weight from about 65,000 g/mol to about 200,000 g/mol.
- 24. (Original) The method according to claim 23, wherein the at least one assist device comprises a coil, a stent, a balloon, or any combination thereof.
- (Currently amended) A method for forming an endovascular occlusion comprising the steps of:
 - a. providing an ion-permeable balloon to a targeted area in a vascular system,
- b. controlling injection of a purified alginate liquid having a high guluronic acid content to the targeted area; and
- c. controlling injection of a calcium chloride solution to the targeted area by injecting the calcium chloride solution into the ion-permeable balloon, wherein the purified alginate liquid is of molecular weight from about 65,000 g/mol to about 200,000 g/mol.
- (Currently amended) A method for forming an endovascular occlusion comprising the steps of:
 - a. providing a balloon to a targeted area in a vascular system, and
- controlling injection of a purified alginate liquid having a high guluronic acid content and injection of a calcium chloride solution to the targeted area,

wherein the alginate liquid and the calcium chloride solution are injected asynchronously, and—wherein the balloon has one or more built-in catheters, and wherein the purified alginate liquid is of molecular weight from about 65,000 g/mol to about 200,000. g/mol.

Application No. 10/738,317 Docket No.: 65306-0092
Amendment dated July 16, 2008

Non-Final Office Action of January 17, 2008

 (Currently Amended) A method for forming an endovascular occlusion comprising the steps of:

- a. providing at least one pre-coated coil to a targeted area in a vascular system, and
- controlling injection of a purified alginate liquid having a high guluronic acid content and injection of a calcium chloride solution to the targeted area,
- wherein injection of the alginate liquid and injection of the calcium chloride solution are at variable injection rates, either within an injection stage or across injection stages, and wherein the purified alginate liquid is of molecular weight from about 65,000 g/mol to about 200,000 g/mol.
- 28. (Original) The method according to claim 27, wherein the coil is pre-coated with at least a conformal coating of alginate gel.
- (Original) The method according to claim 27, wherein the coil is pre-coated with at least a conformal coating of unreacted alginate liquid.
- 30. (Original) The method according to claim 27, wherein the coil is pre-coated with at least calcium chloride ions.
- 31. (Original) The method according to claim 27, wherein the coil is pre-coated with collagen, permeable gel, or polymer material.
- 32. (Original) The method according to claim 28, wherein the coil is modified by ion implantation before placement of the coil in the targeted area.
- 33. (Canceled).
- (Canceled).
- 35. (Previously Presented) The method according to claim 1, wherein the purified alginate liquid has a viscosity less than 25 cP.
- 36. (Canceled).

Application No. 10/738,317 Amendment dated July 16, 2008 Non-Final Office Action of January 17, 2008

37. (Previously presented). The method according to claim 17, wherein the purified alginate liquid has a viscosity less than 25 cP.

Docket No.: 65306-0092

38 - 44. (Withdrawn)